Evidence is mounting that the wildly popular weight-loss medicines known as GLP-1s may also hold potential for treating addiction, and the field may be on the verge of obtaining desperately needed ...

A new study found GLP-1 drugs were associated with 50% fewer substance-related deaths, 39% fewer drug overdoses, and 26% ...

The blockbuster GLP-1 drugs that have reshaped the treatment of diabetes and obesity may help prevent multiple substance use ...

A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes. He didnt ...

A large epidemiological study of more than 600,000 veterans with diabetes suggests GLP-1 weight-loss medications may reduce ...

New research suggests the weight-loss medications could be powerful tools in tackling substance use disorders.

Researchers at Washington University School of Medicine in St. Louis have shown in a new study that GLP-1 medications may be ...

A growing body of research has looked at GLP-1 drugs for alcohol use disorder. A new study shows the medication could have a broader effect on addiction.

SPONSORED: Not sure which GLP-1 is right for you? A St. Joseph Health nurse practitioner explains the key differences between Ozempic, Wegovy, Mounjaro and Zepbound — and why the distinction matters ...

The nonsteroidal mineralocorticoid receptor antagonist finerenone has been reported to improve kidney and cardiovascular outcomes in persons with type 2 diabetes and chronic kidney disease (CKD).

Ozempic, Mounjaro and other GLP-1 drugs for diabetes can prevent the formation of new substance ​use disorders and alleviate ...

Popular GLP-1 receptor agonist drugs for weight loss, also known as GLP-1 RAs, appear to be similarly effective among ...